Archivio dell'Università Alfonso X El Sabio

Assessment of exposure-response relationship for bevacizumab in patients with metastatic colorectal cancer

Mostra i principali dati dell'item

APA

Pena Cabia, Silvia & Royuela Vicente, Ana & Ramos Díaz, Ruth & Gutíerrez Nicolás, Fernando & Peñalver Vera, Ángela & Siso García, Isabel & Hitt Sabag, Ricardo & García Lacalle, Concepción & Peña Cabia, Ana & Iglesias Peinado, Irene & García Díaz, Benito & López Martín, Ana (2021-06 ) .Assessment of exposure-response relationship for bevacizumab in patients with metastatic colorectal cancer.

ISO 690

Pena Cabia, Silvia & Royuela Vicente, Ana & Ramos Díaz, Ruth & Gutíerrez Nicolás, Fernando & Peñalver Vera, Ángela & Siso García, Isabel & Hitt Sabag, Ricardo & García Lacalle, Concepción & Peña Cabia, Ana & Iglesias Peinado, Irene & García Díaz, Benito & López Martín, Ana. 2021-06 .Assessment of exposure-response relationship for bevacizumab in patients with metastatic colorectal cancer.

https://hdl.handle.net/20.500.12080/39709
dc.contributor.author Pena Cabia, Silvia
dc.contributor.author Royuela Vicente, Ana
dc.contributor.author Ramos Díaz, Ruth
dc.contributor.author Gutíerrez Nicolás, Fernando
dc.contributor.author Peñalver Vera, Ángela
dc.contributor.author Siso García, Isabel
dc.contributor.author Hitt Sabag, Ricardo
dc.contributor.author García Lacalle, Concepción
dc.contributor.author Peña Cabia, Ana
dc.contributor.author Iglesias Peinado, Irene
dc.contributor.author García Díaz, Benito
dc.contributor.author López Martín, Ana
dc.date.accessioned 2024-02-12T10:52:14Z
dc.date.available 2024-02-12T10:52:14Z
dc.date.created 2021-06
dc.date.issued 2021-06
dc.identifier.uri https://hdl.handle.net/20.500.12080/39709
dc.description.abstract Limited literature is available for bevacizumab exposure-response relationship and there is not a concentration threshold associated with an optimal disease control. This prospective observational study in patients with metastatic colorectal cancer (mCRC) aims to evaluate, in a real-life setting, the relationship between bev acizumab through concentrations at steady state (Ctrough, SS) and disease control. Ctrough, SS were drawn, coin ciding with the radiological evaluation of the response (progression or clinical benefit). Generalized estimating equations (GEE) analysis was performed. To test the association between Ctrough, SS in each patient with overall survival (OS) or progression-free survival (PFS), Cox proportional hazard models were developed. Data included 50 bevacizumab Ctrough, SS from 27 patients. The GEE model did not suggest any positive association between bevacizumab Ctrough, SS and clinical benefit (OR 0.99, 95% CI: 0.98¿1.02, p = 0.863). The Cox regression showed association between higher median Ctrough, SS with better OS (HR 0.86, 95% CI: 0.73¿1.01, p = 0.060), but not with PFS. We cannot confirm a relationship between bevacizumab Ctrough, SS and clinical benefit but this is the first real-world study trying to show a relationship between bevacizumab Ctrough, SS and disease control in mCRC. It was conducted in a small sample size which reduces the level of evidence. Further controlled randomized studies with a sufficient number of patients are required. es_ES
dc.format application/pdf es_ES
dc.language eng es_ES
dc.rights CC-BY es_ES
dc.rights.uri http://creativecommons.org/licenses/by/4.0/deed.es es_ES
dc.title Assessment of exposure-response relationship for bevacizumab in patients with metastatic colorectal cancer es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.rights.accessrights info:eu-repo/semantics/openAccess es_ES
dc.identifier.location N/A es_ES


Files in questo item

Questo item appare nelle seguenti collezioni

Mostra i principali dati dell'item

CC-BY Except where otherwise noted, this item's license is described as CC-BY

Cerca in DSpace


Ricerca

My Account

Social Media